drugset / Trial / NCT03276962

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

NCT03276962

Phase 2 Completed 1500 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

The study intends to establish proof of concept for a fractional dose schedule under conditions of natural exposure in children 5-17 months old at first vaccination. The study also aims to establish the role of third dose spacing in a fractional dose schedule, describe the effect of an earlier full fourth dose at Month 14 and describe the effect of multiple fractional or full yearly doses.

Timeline

Start
2017-09-28
Primary completion
2019-11-04
Completion
2022-11-14

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject RTS,S/AS01E Vaccine 0.1 ml Intramuscular
Subject RTS,S/AS01E Vaccine 0.5 ml Intramuscular
Subject Rabies vaccine Vaccine 0.1 ml Intramuscular

Indications